|
|
|
Volumn 20, Issue 5, 2014, Pages E10-
|
|
FDA grants accelerated approval for ibrutinib for CLL
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
IBRUTINIB;
PYRAZOLE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEGISLATION AND JURISPRUDENCE;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
MULTICENTER STUDY (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II AS TOPIC;
DRUG APPROVAL;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
MULTICENTER STUDIES AS TOPIC;
PYRAZOLES;
PYRIMIDINES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84941212125
PISSN: None
EISSN: 19362692
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|